Xuelin (Steve) Wang
Lawyers
Filters
Laekna HK$587 million placement of shares
We advised Laekna on the placement of new shares
GenFleet Therapeutics HK$1.82 billion IPO
We advised GenFleet on its IPO and HKEX listing
Ascletis HK$861.98 million placement of shares and top-up subscription
We advised the placing agent on the placement and the top-up subscription
Adagene $25 million strategic equity investment from Sanofi
We advised Adagene on the transaction
Medtide HK$411.2 million IPO
We advised Medtide on its IPO and HKEX listing
Mirxes Holding Company HK$1.09 billion IPO
We advised Mirxes on its IPO and HKEX listing
PegBio IPO
We advised PegBio on its IPO and HKEX listing
Visen Pharmaceutical HK$783.3 million IPO
The shares are listed on the HKEX
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S. listing
BrainAurora Medical Technology HK$583 million IPO
We advised BrainAurora on its IPO and HKEX listing